SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

TROV RSS Feed
Add TROV Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/16/2017 8:15:30 PM - Followers: 53 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
USA
 
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
E-mail:  service@trovagene.com
http://trovagene.com/
 
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
 
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.

Highlights:

Trovagene Closes Acquisition of CLIA Laboratory Assets
 
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
 
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
 
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
 
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board


Targeted $40 Billion market space:
TROV market space



SureTrader
Interactive Brokers Advertisement
TROV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Securities Registration Statement (s-1/a) 05:05 PM
TROV News: Current Report Filing (8-k) 11/13/2017 08:10:10 AM
TROV News: Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 11/13/2017 08:00:00 AM
TROV News: Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results 11/09/2017 10:32:00 AM
TROV News: Current Report Filing (8-k) 11/09/2017 09:44:01 AM
News News Alert: Securities Registration Statement (s-1/a) 11/17/2017 05:05:46 PM
PostSubject
#941   Added another 15k shares again today. Insanely abused! briphelps 11/16/17 08:15:30 PM
#940   Picked up 35k shares yesterday. Waiting for more briphelps 11/16/17 08:20:18 AM
#939   Worth $1-$2 billion is the next two years! briphelps 11/14/17 09:08:37 AM
#938   Still time to get in cheap. Like shooting GotDrys 11/13/17 06:33:34 AM
#937   But this really cheap right now!!! GotDrys 11/10/17 10:35:18 AM
#936   Wake me when the action begins here. Butchmass 10/20/17 04:28:46 PM
#935   We need some thing to get the bid Butchmass 10/20/17 09:57:26 AM
#934   * * $TROV Video Chart 10-18-17 * * ClayTrader 10/18/17 05:04:13 PM
#933   Nice bounce off the day's lows. Watching... TROV Lone Wolf 10/18/17 10:41:03 AM
#932   No, this is the area I bought my Butchmass 10/18/17 10:40:12 AM
#931   Did you pick up any? KOmani 10/18/17 10:28:24 AM
#930   Yes, it is possible. KOmani 10/18/17 09:58:54 AM
#929   Wow. Nice pop on the news but Butchmass 10/18/17 09:40:15 AM
#928   Looking at some nice upside! crudeoil24 10/18/17 09:22:29 AM
#927   At least we know where the resistances /supports PAC 10/18/17 08:33:10 AM
#926   TROV 's got news out this morning. Lone Wolf 10/18/17 08:16:18 AM
#925   At least for today we have moved up Butchmass 10/12/17 03:35:25 PM
#924   Possible $1 test #2 today.... I Need Money 10/10/17 08:41:26 AM
#923   Double bottom. Did not see that. JohnCM 10/10/17 08:19:46 AM
#922   I'm thinking it tests a buck again.... I Need Money 10/09/17 11:17:11 AM
#921   I'm just watching at the moment. If it sssss1 10/09/17 11:15:41 AM
#920   I bought a few on this dip. Watching.... I Need Money 10/09/17 10:56:40 AM
#919   Sell on news sssss1 10/09/17 10:55:59 AM
#918   Good news, whys she dropping I Need Money 10/09/17 10:38:04 AM
#917   Here comes some big volume jonnyvs 10/09/17 09:08:02 AM
#916   Great call ;) c stock1ace1 10/09/17 08:41:56 AM
#915   PR out! Boom! jonnyvs 10/09/17 08:14:52 AM
#914   PR Monday in my opinion .... ;) jonnyvs 10/06/17 07:08:59 PM
#913   Thanks for checking for us. The Rainmaker 10/06/17 07:05:00 PM
#912   * * $TROV Video Chart 10-06-17 * * ClayTrader 10/06/17 04:34:13 PM
#911   PR AH today or PM Monday should easily jonnyvs 10/06/17 02:56:48 PM
#910   Nice climb from lows, steady buys, solid news Full Contact Yoga 10/06/17 02:45:09 PM
#909   FDA news is true. Company says it's putting jonnyvs 10/06/17 12:53:34 PM
#908   Risk some to make something. Hope it dips PAC 10/06/17 09:25:58 AM
#907   100% agree jonnyvs 10/06/17 09:21:38 AM
#906   True. The Biotechs closest to $1 seem Lone Wolf 10/06/17 09:19:25 AM
#905   doesn't mean it won't reclaim. We shall see PAC 10/06/17 08:52:25 AM
#904   Up 45% < > weakening in my math Lone Wolf 10/06/17 08:50:50 AM
#903   If news is legit, this crushes 1.50 today jonnyvs 10/06/17 08:46:30 AM
#902   Kinda early for TROV to be weakening already. PAC 10/06/17 08:44:14 AM
#901   TROV's looking good here partner! ;-) Lone Wolf 10/06/17 08:39:43 AM
#900   TROV NEWS= https://stocknews.com/news/trov-granted-orphan-drug-designation-by-the-fda-for-its [SMART MONEY] 10/06/17 08:16:38 AM
#899   Where did you find that he purchased shares. stockmule 09/11/17 06:54:48 PM
#898   Looks like there is not much interest on EliminatetheCaliphat 08/22/17 04:22:19 PM
#897   Huge Buy on 08/15/2017 by Trovagene's CEO..... n3m3sis 08/17/17 05:57:05 PM
#896   Hedge fund accumulation? Todays news could propel a biotechnician 07/27/17 09:59:47 AM
#895   Any news could send the stock over $2, Maple tree 07/14/17 03:34:27 PM
#894   TROV will go to multidollar range and it Maple tree 07/14/17 09:40:23 AM
#893   Good opportunity to load this morning Maple tree 07/14/17 09:10:10 AM
#892   Gap up stock!! Ericj5592 07/12/17 09:12:14 AM
PostSubject